• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Polyrizon Ltd.

    12/5/25 6:52:44 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PLRZ alert in real time by email
    6-K 1 ea0268528-6k_polyrizon.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    Report of Foreign Private Issuer

    Pursuant to Rule 13a-16 or 15d-16

    under the Securities Exchange Act of 1934

     

    For the month of December 2025

     

    Commission file number: 001-42375

     

    Polyrizon Ltd.

    (Translation of registrant’s name into English)

     

    5 Ha-Tidhar Street

    Raanana, 4366507, Israel

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒   Form 40-F ☐

     

     

     

     

     

     

    CONTENTS

     

    On December 5, 2025, Polyrizon Ltd. (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with investors for the purchase and sale of 552,269 of the Company’s ordinary shares, no par value per share (the “Ordinary Shares”), in a registered direct offering (the “Offering”) at a purchase price of $9.00 per Ordinary Share. The offering price represented a premium to the Nasdaq Minimum Price under Listing Rule 5635(d).

     

    The Offering is expected to close on or about December 5, 2025, subject to the satisfaction of customary closing conditions. The aggregate gross proceeds to the Company are expected to be approximately $4.97 million. The Company expects to use the net proceeds from the Offering, together with its existing cash, for general corporate purposes, which include financing our operations, capital expenditures and business development, technology development, and for pursuing strategic opportunities, including but not limited to, strategic acquisitions.

     

    The Securities Purchase Agreement also contain representations, warranties, indemnification and other provisions customary for transactions of this nature. In addition, the Company agreed to pay Aegis Capital Corp a financial advisory fee of $250,000.

     

    The securities described above and to be issued in the Offering are being issued pursuant to a prospectus supplement dated as of December 5, 2025, which will be filed with the Securities and Exchange Commission, in connection with a takedown from the Company’s shelf registration statement on Form F-3 (File No. 333-291368) (the “Registration Statement”), which became effective on December 3, 2025, and the base prospectus dated as of December 3, 2025 contained in such Registration Statement. This Report on Form 6-K (this “Report”) shall not constitute an offer to sell or the solicitation to buy, nor shall there be any sale of, any of the securities described herein in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

     

    A copy of the Securities Purchase Agreement is filed as Exhibit 10.1 to this Report and is incorporated by reference herein. The foregoing summary of such document is subject to, and qualified in its entirety by reference to, such exhibit.

     

    A copy of the opinion of Meitar | Law Offices relating to the securities issued in the Offering is attached as Exhibit 5.1.

      

    This Report is incorporated by reference into the Company’s Registration Statements on Form S-8 (File No. 333-284410 and 333-288923) and Form F-3 (333-291368), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

     

    Forward Looking Statements

     

    This Report contains statements which constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward looking statements are based upon the Company’s present intent, beliefs or expectations, but forward looking statements are not guaranteed to occur and may not occur for various reasons, including some reasons which are beyond the Company’s control. For example, this Report states that the Offering is expected to close on or about December 5, 2025. In fact, the closing of the Offering is subject to various conditions and contingencies as are customary in securities purchase agreements in the United States. If these conditions are not satisfied or the specified contingencies do not occur, this Offering may not close. For this reason, among others, you should not place undue reliance upon the Company’s forward looking statements. Except as required by law, the Company undertakes no obligation to revise or update any forward looking statements in order to reflect any event or circumstance that may arise after the date of this Report on Form 6-K.

     

    1

     

     

    EXHIBIT INDEX

     

    Exhibit No.    
    5.1   Opinion of Meitar | Law Offices, Israeli counsel to the Company
    10.1   Form of Securities Purchase Agreement
    23.1   Consent of Meitar | Law Offices (included in Exhibit 5.1)

     

    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      Polyrizon Ltd.
       
    Date: December 5, 2025 By: /s/ Tomer Izraeli
      Name:  Tomer Izraeli
      Title: Chief Executive Officer

     

     

    3

     

    Get the next $PLRZ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PLRZ

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PLRZ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program

    Ra'anana, Israel, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a biotechnology company focusing on the development of intranasal products, today announced new results from its ongoing preclinical evaluation of its proprietary intranasal naloxone hydrogel formulation, demonstrating promising permeation kinetics that complement the Company's previously reported stability and mucoadhesion successes. Following the positive mucoadhesion findings-where Polyrizon's formulation showed significantly enhanced persistence on ex-vivo nasal tissue compared to a marketed intranasal naloxone product (p < 0.0001) -the Company has completed a dedicated se

    12/11/25 8:15:00 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray

    Ra'anana, Israel, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a biotechnology company focusing on the development of intranasal products, today announces that it has successfully completed a pre-submission meeting with the U.S. Food and Drug Administration (FDA) regarding its PL-14 Allergy Blocker product, a novel nasal spray designed to provide protective intranasal barrier functionality. During the meeting, Polyrizon presented the general development program plan for PL-14, including the proposed manufacturing process, analytical and quality controls, and the structure of the stability program that will support future regulatory submis

    12/8/25 8:55:00 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal Protection

    Ra'anana, Israel , Dec. 04, 2025 (GLOBE NEWSWIRE) -- In an era where airborne threats like allergens and viruses disrupt daily life for millions, a small biotech innovator in Israel is quietly reshaping approaches to respiratory defense. Polyrizon Ltd. (NASDAQ:PLRZ), a development-stage biotechnology company, aims to transform a bold lab-born vision into a scalable reality. With the recent announcement of a pivotal manufacturing milestone, Polyrizon is no longer just a promising startup—it is advancing its efforts to develop non-pharmacological solutions that could shield global populations from seasonal woes and beyond. Founded by visionary entrepreneur Tomer Izraeli, Polyrizon emerged

    12/4/25 7:32:00 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PLRZ
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Polyrizon Ltd.

    SCHEDULE 13G - Polyrizon Ltd. (0001893645) (Subject)

    12/12/25 4:15:19 PM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Polyrizon Ltd.

    6-K - Polyrizon Ltd. (0001893645) (Filer)

    12/11/25 8:21:36 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Polyrizon Ltd.

    6-K - Polyrizon Ltd. (0001893645) (Filer)

    12/8/25 9:00:01 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PLRZ
    Leadership Updates

    Live Leadership Updates

    View All

    Polyrizon Appoints Dr. Michal Meir as Senior Director of Regulatory and Clinical Affairs

    Raanana, Israel, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announce today the appointment of Dr. Michal Meir, Senior Consultant at MedTech SME Ltd., as Senior Director of Regulatory and Clinical Affairs. The appointment was made as part of the Company's preparations towards its clinical trial for PL-14 that is expected to commence in 2025. Dr. Meir brings over a decade of experience in the medical device and pharmaceutical industries, with a proven track record in regulatory strategy, clinical affairs management and product developmen

    12/19/24 7:22:00 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Polyrizon Announces Appointment of VP of Regulatory Affairs and Quality Assurance

    Raanana, Israel, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announces today the appointment of Asaf Azulay, the Managing Director of Eurofins' Li-Med team, to its leadership as its VP of Regulatory Affairs and Quality Assurance (RA/QA). This strategic appointment reflects Polyrizon's ongoing commitment to maintaining the highest industry standards as it advances its pipeline of cutting-edge solutions. Asaf Azulay brings over 20 years of extensive experience in the medical devices industry, with expertise in leading quality teams and i

    12/13/24 6:25:00 AM ET
    $PLRZ
    Biotechnology: Pharmaceutical Preparations
    Health Care